HBV-3 is developed by Beijing Center for Disease Control and Prevention.

What development phase is HBV-3 in?

HBV-3 is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

HBV-3

Beijing Center for Disease Control and Prevention · FDA-approved active Biologic Quality 6/100

At a glance

Generic name	HBV-3
Sponsor	Beijing Center for Disease Control and Prevention
Modality	Biologic
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Follow-up Study 16-20 Years After Primary Vaccination Against Hepatitis B of Newborns From HBeAg+ & HBsAg+ Mothers (PHASE4)
The Safety and Immunogenicity Research of Live Attenuated Varicella Vaccine After the 2 Doses Vaccination (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

HBV-3 CI brief — competitive landscape report
HBV-3 updates RSS · CI watch RSS
Beijing Center for Disease Control and Prevention portfolio CI